Avoiding viral contamination in biotechnological and pharmaceutical processes.
Henzler
H J
HJ
Biotechnological Processes Group, Bayer AG, Leverkusen, Germany.
Kaiser
K
K
D000818:Animals; D001688:Biological Products; D001709:Biotechnology; D002417:Cattle; D007562:Creutzfeldt-Jakob Syndrome / Q000635:transmission / Q000821:virology; D001908:Diarrhea Viruses, Bovine Viral / Q000302:isolation & purification / Q000472:pathogenicity; D004203:Disinfection / Q000379:methods; D004340:Drug Contamination / Q000517:prevention & control*; D006564:Herpesviridae / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D009052:Leukemia Virus, Murine / Q000302:isolation & purification / Q000472:pathogenicity; D051379:Mice; D010321:Parvoviridae / Q000302:isolation & purification / Q000472:pathogenicity; D011328:Prions / Q000302:isolation & purification / Q000472:pathogenicity; D012449:Safety; D014462:Ultrafiltration; D014780:Viruses / Q000302:isolation & purification* / Q000472:pathogenicity
D001688:Biological Products; D011328:Prions